Acta Crystallographica Section E Structure Reports Online

ISSN 1600-5368

## Richard J. Bowen,<sup>a</sup> E. Mabel Coyanis,<sup>a</sup> Marcus Layh,<sup>a</sup> Reinout Meijboom<sup>b</sup>\* and Craig B. Poole<sup>c</sup>

<sup>a</sup>School of Chemistry, University of the Witwatersrand, Johannesburg, Private Bag 3, Wits 2050, South Africa, <sup>b</sup>Department of Chemistry, University of the Free State, PO Box 339, Bloemfontein 9300, South Africa, and <sup>c</sup>Faculty of Health, Human Services and Applied Science, Southbank Institute of TAFE, South Brisbane, 4101 Queensland, Australia

Correspondence e-mail: meijboomr.sci@mail.uovs.ac.za

#### Key indicators

Single-crystal X-ray study T = 173 K Mean  $\sigma$ (C–C) = 0.003 Å R factor = 0.031 wR factor = 0.074 Data-to-parameter ratio = 19.7

For details of how these key indicators were automatically derived from the article, see http://journals.iucr.org/e.

# Bis[bis(diphenylphosphino)ethane]rhodium(I) tetraphenylborate

In the title compound,  $[Rh(C_{26}H_{24})_2](C_{24}H_{20}B)$ , both the Rh and the B atom lie on twofold axes of symmetry. Selected geometrical parameters are Rh-P = 2.3076 (5) and 2.3114 (5) Å, and P-Rh-P = 82.43 (2) and 98.11 (2)°.

Received 23 November 2005 Accepted 6 December 2005 Online 14 December 2005

### Comment

The lipophilic bis-chelated 1:2  $M^{I}$  diphosphine complexes  $[M(dppe)_2]X$  [where M = Au, Ag and Cu, dppe =  $Ph_2P(CH_2)_2PPh_2$  and X is a non-coordinating anion] exhibit antitumour activity against a range of tumour models [see Berners-Price et al. (1990); Berners-Price, Bowen, Galettis et al. (1999); Berners-Price, Bowen, Hambley & Healy (1999) for examples]. Since the dppe ligand is itself cytotoxic (Mirabelli et al., 1987), albeit less potent than  $[M(dppe)_2]X$ , it has been suggested that the phosphine is the antitumour agent and the role of the metal may largely be to protect the phosphine and deliver it to target sites. Conversely, the Rh<sup>I</sup> complex [RhCl(PPh<sub>3</sub>)dppe] and the complexes  $[M'Cl_2(dppe)]$ , where M' is Pt<sup>II</sup>, Pd<sup>II</sup> and Ni<sup>II</sup>, are all inactive. In this work, we sought to test the antitumor activity and various propositions for explaining this activity by examination of the  $[M(dppe)_2]X$ class of compounds. We report here the preparation and structure of [Rh(dppe)<sub>2</sub>][BPh<sub>4</sub>], (I). Though initial tests on compound (I) seem to indicate that the complex is inactive, we will communicate the biological data elsewhere.



The structure of (I) does not show any unexpected features. The coordination around the Rh atom is approximately square planar, the distortion being due to the twofold crystallographic symmetry. This distortion can be seen from the dihedral angle of 12.67 (2)° between the planes defined by P1/Rh/P2 and P1<sup>i</sup>/Rh/P2<sup>i</sup> [symmetry code: (i) 1 - x,  $y, \frac{1}{2} - z$ ]. In each phosphine the two aliphatic C atoms bridging the two phosphorus atoms are not equally positioned on either side of the P/Rh/P plane. The dominant feature of the five-membered chelate ring is the staggered conformation about the C–C bond. The bite angle of the dppe ligands in the title compound is 82.43 (2)°. This value compares well with other cationic rhodium–dppe complexes reported in literature.

### Experimental

[Rh(NBD)Cl]<sub>2</sub> (NBD = norbornadiene) was kindly provided by Dr A. Muller (University of the Free State). All other chemicals were

Printed in Great Britain - all rights reserved

© 2006 International Union of Crystallography

# metal-organic papers

used as received. A solution of 1,2-bis(diphenylphosphino)ethane (0.50 g, 1.25 mmol) in dichloromethane (5 ml) was slowly added to a solution of  $[Rh(NBD)Cl]_2$  (0.145 g, 0.31 mmol) in dichloromethane (5 ml). After stirring for 1 h a solution of NaBPh<sub>4</sub> (0.22 g, 0.64 mmol) in ethanol (5 ml) was added. The resulting mixture was stirred for 4 h and filtered. The volatiles were removed *in vacuo*. The residue was taken up in acetone, filtered, and the solvent was removed *in vacuo* to give the title compound as a yellow powder. Recrystallization from dichloromethane afforded crystals suitable for X-ray diffraction. All analytical data were in agreement with the literature (Faraone, 1975).

### Crystal data

$[Rh(C_{26}H_{24}P_2)_2](C_{24}H_{20}B)$	$D_x = 1.33 \text{ Mg m}^{-3}$		
$M_r = 1218.9$	Mo $K\alpha$ radiation		
Monoclinic, $C2/c$	Cell parameters from 977		
a = 17.010 (2) Å	reflections		
b = 16.560 (2)  Å	$\theta = 2.6-28.2^{\circ}$		
c = 22.142 (3) Å	$\mu = 0.43 \text{ mm}^{-1}$		
$\beta = 102.642 \ (2)^{\circ}$	T = 173 (2) K		
$V = 6086.0 (13) \text{ Å}^3$	Cuboid, yellow		
Z = 4	$0.2 \times 0.2 \times 0.19 \text{ mm}$		
Data collection			
Bruker SMART CCD 1K	7320 independent reflections		
diffractometer	5664 reflections with $I > 2\sigma(I)$		

diffractometer  $\omega$  scans Absorption correction: multi-scan (*SADABS*; Bruker, 1998)  $T_{min} = 0.919, T_{max} = 0.923$ 20334 measured reflections

#### Refinement

Refinement on $F^2$	H-atom parameters constrained
$R[F^2 > 2\sigma(F^2)] = 0.031$	$w = 1/[\sigma^2(F_o^2) + (0.0346P)^2]$
$wR(F^2) = 0.074$	where $P = (F_0^2 + 2F_c^2)/3$
S = 1.04	$(\Delta/\sigma)_{\rm max} = 0.001$
7320 reflections	$\Delta \rho_{\rm max} = 0.39 \ {\rm e} \ {\rm \AA}^{-3}$
371 parameters	$\Delta \rho_{\rm min} = -0.37 \ {\rm e} \ {\rm \AA}^{-3}$

 $R_{\rm int} = 0.037$ 

 $h = -19 \rightarrow 22$ 

 $k = -19 \rightarrow 21$ 

 $l=-29\rightarrow 27$ 

 $\theta_{\rm max} = 28^\circ$ 

### Table 1

Selected geometric parameters (Å, °).

Rh-P2	2.3076 (5)	P2-C2	1.8410 (18)
Rh-P1	2.3114 (5)	B-C61	1.644 (3)
P1-C11	1.8326 (19)	B-C51	1.648 (3)
P1-C21	1.8358 (18)	C1-C2	1.527 (2)
P1-C1	1.8484 (18)		
P2-Rh-P2 <sup>i</sup>	169.75 (3)	P1 <sup>i</sup> -Rh-P1	173.98 (3)
P2-Rh-P1 <sup>i</sup>	98.110 (18)	$C61^{ii} - B - C61$	115.1 (2)
P2-Rh-P1	82.432 (18)	C61 <sup>ii</sup> -B-C51 <sup>ii</sup>	103.31 (9)
P1-C1-C2-P2	-49.41 (15)		

Symmetry codes: (i) -x + 1, y,  $-z + \frac{1}{2}$ ; (ii) -x + 2, y,  $-z + \frac{1}{2}$ .

The aromatic and methylene H atoms were placed in geometrically idealized positions (C-H = 0.95 and 0.99 Å, respectively) and constrained to ride on their parent atoms with  $U_{\rm iso}(H) = 1.2U_{\rm eq}(C)$ .

Data collection: *SMART-NT* (Bruker, 1998); cell refinement: *SAINT-Plus* (Bruker, 1999); data reduction: *SAINT-Plus* and *XPREP* (Bruker, 1999); program(s) used to solve structure: *SHELXS97* (Sheldrick, 1997); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *DIAMOND* (Brandenburg & Berndt, 2001); software used to prepare material for publication: *WinGX* (Farrugia, 1999).





The structure of (I), showing 50% probability displacement ellipsoids. H atoms have been omitted for clarity. For the aromatic C atoms, the first digit indicates ring number and the second digit indicates the position of the atom in the ring. [Symmetry codes: (') 1 - x, y,  $\frac{1}{2} - z$ ; ('') 2 - x, y,  $\frac{1}{2} - z$ .]

Financial assistance from the South African National Research Foundation and the Research Funds of the Universities of Witwatersrand and the Free State is gratefully acknowledged. Mintek (project AuTek) is gratefully acknowledged for a postdoctoral bursary for EMC. The University of the Witwatersrand (Professor D. Levendis, Dr D. G. Billing and Dr M. Fernandes) is thanked for the use of its diffractometer. Part of this material is based on work supported by the South African National Research Foundation GUN 2038915, University of the Free State. Opinions, findings, conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the NRF.

### References

- Berners-Price, S. J., Bowen, R. J., Galettis, P., Healy, P. C. & McKeage, M. J. (1999). Coord. Chem. Rev. 185–186, 823–836.
- Berners-Price, S. J., Bowen, R. J., Hambley, T. W. & Healy, P. C. (1999). J. Chem. Soc. Dalton Trans. pp. 1337–1346.
- Berners-Price, S. J., Girard, G. R., Hill, D. T., Sutton, B. M., Jarret, P. S., Faucette, L. F., Johnson, R. K., Mirabelli, C. K. & Sadler, P. J. (1990). J. Med. Chem. 33, 1386–1392.
- Brandenburg, K. & Berndt, M. (2001). *DIAMOND*. Release 2.1e. Crystal Impact, Postfach 1251, D-53002, Bonn.
- Bruker (1998). SADABS (Version 2004/1) and SMART-NT (Version 5.050). Bruker AXS Inc., Madison, Wisconsin, USA.
- Bruker (1999). SAINT-Plus. Version 6.02 (including XPREP). Bruker AXS Inc., Madison, Wisconsin, USA.
- Faraone, F. (1975). J. Chem. Soc. Dalton Trans. pp. 541-545.
- Farrugia, L. J. (1999). J. Appl. Cryst. 32, 837-838.
- Mirabelli, C. K., Hill, D. T., Faucette, L. F., McCabe, F. L., Girard, G. R., Bryan, D. L., Sutton, B. M., Bartus, J. O. L., Crooke, S. T. & Johnson, R. J. (1987). J. Med. Chem. **30**, 2181–2190.
- Sheldrick, G. M. (1997). SHELXL97 and SHELXS97. University of Göttingen, Germany.